Intermittent ART in Primary HIV Infection (PHI-IL2)
Juan A. Arnaiz
Information provided by (Responsible Party)
Juan A. Arnaiz, Hospital Clinic of Barcelona
First received: November 18, 2014
Last updated: November 21, 2014
Last Verified: November 2014
History of Changes
Interventions during primary HIV infection (PHI) can modify the immune control and the clinical evolution during the chronic phase. Although several studies suggest the benefit of antiretroviral treatment (ART) during PHI, indication of ART is still not universally recommended. The investigators randomized patients with PHI, with a favourable immunological profile and well controlled on ART, to undergone structured treatment interruptions alone or with low doses of IL-2, stopping ART thereafter. The endpoints were immune control of HIV replication and time to resume ART. Immunological profile, specific CD4 and CD8 responses and clinical data were analysed for both groups up to 48 weeks, and during a long follow-up, up to nine years since final ART stop.
Drug : Antiretroviral therapy plus Interleukin-2
Drug : Antiretroviral therapy alone
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Long Term Follow-up of Patients Experiencing Structured Treatment Interruption (STI) With or Without Low Doses of Interleukin-2 During Primary HIV Infection (PHI)|
Further study details as provided by Juan A. Arnaiz, Hospital Clinic of Barcelona:
Primary Outcome Measures
- Control of viral replication without ART. [ Time Frame: 48 weeks ]
- Time to resume ART. [ Time Frame: 9 years after final stop ]
|Study Start Date:||March 2000|
|Study Completion Date:||April 2013|
|Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
Antiretroviral therapy alone
Antiretroviral therapy alone
Standard antiretroviral therapy
Antiretroviral therapy plus Interleukin-2'
Antiretroviral therapy plus Interleukin-2
Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
The study design included two phases. The first phase consisted in four STI of 8 weeks each (off-ART), separated by 16 weeks of treatment -or the time necessary to reach again to PVL <20 copies/mL- (on-ART). At the end of the 4th off-ART cycle (week 0) an interim evaluation was performed and the second phase initiated. During the second phase, the first 6 patients received ART until they reach PVL<20 copies/mL, discontinuing thereafter (final stop). The last 6 patients received ART and low doses of IL-2. ARV therapy was stopped after reaching PVL<20 copies/mL (final stop) and IL-2 after 6 months of treatment. IL-2 was prescribed at a dose of 750.000 UI/m2 daily and was self-administrated in all patients previous trained by a specialized nurse. ART was resumed in patient dropping CD4 cell count less than 350 cell/mm3 in two consecutive determinations or in patients who developed opportunistic infections. A long term follow up analysis was performed at 3, 6 and 9 years since the final stop. It included time to resume ART, clinical events, survival rate, CD4-CD8-CD4/CD8 ratio.Eligibility
|Ages Eligible for Study:||18 Years and older|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- PHI defined by detectable plasma viral load (PVL) or p24 antigen detection coupled with a negative or indeterminate LIA assay (according CDC criteria); negative HIV-1 EIA in the preceding 90 days or by a positive EIA and LIA assay with acute retroviral syndrome in the preceding 90 days of starting ART plus documented negative HIV-1 EIA within the previous year.
- ART started within 90 days from the HIV exposure and continuing in the same treatment at least 12 months before the inclusion, and they must have shown good virological and immunological responses, defined as undetectable PVL (<20 copies/mL in the last two controls) and CD4 more than 500 cells/mm3 with a CD4/CD8 ratio >1 in the last 8 months previous to enrolment
- Infection of more than 90 days.
- Age under 18 years old.
- AIDS defining condition
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02300623
Locations Show More
|Hospital Clinic de Barcelona|
|Barcelona, Spain, 08036|
Sponsors and CollaboratorsJuan A. Arnaiz
|Principal Investigator:||Josep Maria Miró, MDPhD||Hospital Clinic of Barcelona|
|Responsible Party:||Juan A. Arnaiz, MD, Hospital Clinic of Barcelona|
|ClinicalTrials.gov Identifier:||NCT02300623 History of Changes|
|Other Study ID Numbers:||PHI-IL2|
|Study First Received:||November 18, 2014|
|Last Updated:||November 21, 2014|
Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
ClinicalTrials.gov processed this data on March 16, 2018
This information is provided by ClinicalTrials.gov.